<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02775864</url>
  </required_header>
  <id_info>
    <org_study_id>7226</org_study_id>
    <nct_id>NCT02775864</nct_id>
  </id_info>
  <brief_title>Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia</brief_title>
  <official_title>Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rutgers University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a retrospective cohort study of adults with schizophrenia that will compare
      outcomes of new users of alternative psychotropic medication strategies using 10 years of
      Medicaid data. The primary comparative effectiveness analyses will focus on subgroups of
      patients with schizophrenia facing common clinical situations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This retrospective cohort study will use data from national (45-state) Medicaid Analytic
      Extracts data (2001-2010). The cohort will consist of adults who are 18 to 64 years old and
      diagnosed with schizophrenia who initiate a new psychotropic medication after a period of
      stable antipsychotic treatment.

      The eligibility criteria select a cohort of individuals diagnosed with schizophrenia, have
      received antipsychotic monotherapy prior to the index date, and are still experiencing
      problems for which a new psychotropic medication strategy was initiated. A 1-year period of
      eligibility prior to follow-up initiation ensures sufficient time to collect service use
      related covariates to characterize cohort members.

      Five clinical subgroups will be defined based on the presence of psychiatric diagnoses during
      the 30 days prior to and inclusive of the treatment change under study (index date) and who
      have this same diagnostic code from more than one provider to increase the validity of the
      diagnostic groups. The subgroups will be defined by codes to capture 1) uncomplicated
      schizophrenia; 2) schizoaffective disorder; 3) depression; 4) mania; and 5) anxiety. These
      subgroups are defined to reflect the reason for the change in treatment.

      Pharmacological treatment options for patients with schizophrenia who are nonresponsive to
      antipsychotic monotherapy will include (1) initiation of a second antipsychotic, (2)
      initiation of an antidepressant, (3) initiation of a mood stabilizer and (4) initiation of a
      benzodiazepine.

      The primary effectiveness outcome will be time to psychiatric hospitalization. Secondary
      measures include time to index treatment discontinuation, time to introduction of another
      psychotropic medication, psychiatric emergency department visits, all-cause hospitalization,
      and death.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">April 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Psychiatric Hospitalization</measure>
    <time_frame>One year</time_frame>
    <description>Number of participants hospitalized for a mental health reason</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Emergency Department Visit for Mental Health Reason</measure>
    <time_frame>One year</time_frame>
    <description>Number of Participants with an Emergency Department visit for mental health reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>One year</time_frame>
    <description>Participants who died</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">81921</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Antipsychotic</arm_group_label>
    <description>Individuals initiating treatment with an antipsychotic medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antidepressant</arm_group_label>
    <description>Individuals initiating treatment with an antidepressant medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benzodiazepine</arm_group_label>
    <description>Individuals initiating treatment with a benzodiazepine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mood stabilizer</arm_group_label>
    <description>Individuals initiating treatment with a mood stabilizer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antipsychotic</intervention_name>
    <description>New initiation of any antipsychotic medication</description>
    <arm_group_label>Antipsychotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antidepressant</intervention_name>
    <description>New initiation of any antidepressant medications</description>
    <arm_group_label>Antidepressant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzodiazepine</intervention_name>
    <description>New initiation of any benzodiazepine</description>
    <arm_group_label>Benzodiazepine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mood stabilizer</intervention_name>
    <description>New initiation of lithium or any mood stabilizing anti-epileptic drug</description>
    <arm_group_label>Mood stabilizer</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults diagnosed with schizophrenia who are taking only a single antipsychotic medication
        who initiate treatment with an additional psychotropic medication.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The data source will be national (45-state) Medicaid Analytic Extracts data
             (2001-2010). The cohort will consist of adults who are 18 to 64 years old and
             diagnosed with schizophrenia who initiate a new psychotropic medication after a period
             of stable antipsychotic treatment.

               -  Schizophrenia will be defined as ≥2 outpatient claims or ≥1 inpatient claim for
                  schizophrenia [ICD-9-CM: 295] during 365 days of consecutive Medicaid enrollment
                  immediately prior to the index date. Stable antipsychotic monotherapy will be
                  defined by filled prescriptions for only one second-generation antipsychotic, and
                  no other psychotropics, for ≥ 90 days immediately preceding the start of the
                  index medication (t0). After the ≥90 days of stable treatment with a single
                  second-generation antipsychotic, study patients will have had a change in therapy
                  defined as (1) addition of a second antipsychotic or (2) addition of a different
                  psychotropic drug class (antidepressant, mood stabilizer, or benzodiazepine). To
                  ensure the patients are in active treatment there must be an active supply of
                  antipsychotic medication on t0.

        Exclusion Criteria:

          -  Medicare recipients

          -  Patients receiving clozapine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 13, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <results_first_submitted>May 10, 2018</results_first_submitted>
  <results_first_submitted_qc>March 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 7, 2019</results_first_posted>
  <last_update_submitted>March 7, 2019</last_update_submitted>
  <last_update_submitted_qc>March 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Scott Stroup</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 23, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT02775864/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Antipsychotic</title>
          <description>Individuals initiating treatment with an antipsychotic medication
Antipsychotic: New initiation of any antipsychotic medication</description>
        </group>
        <group group_id="P2">
          <title>Antidepressant</title>
          <description>Individuals initiating treatment with an antidepressant medication
Antidepressant: New initiation of any antidepressant medications</description>
        </group>
        <group group_id="P3">
          <title>Benzodiazepine</title>
          <description>Individuals initiating treatment with a benzodiazepine
Benzodiazepine: New initiation of any benzodiazepine</description>
        </group>
        <group group_id="P4">
          <title>Mood Stabilizer</title>
          <description>Individuals initiating treatment with a mood stabilizer
Mood stabilizer: New initiation of lithium or any mood stabilizing anti-epileptic drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26014"/>
                <participants group_id="P2" count="31117"/>
                <participants group_id="P3" count="11941"/>
                <participants group_id="P4" count="12849"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22772"/>
                <participants group_id="P2" count="26218"/>
                <participants group_id="P3" count="10081"/>
                <participants group_id="P4" count="10765"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3242"/>
                <participants group_id="P2" count="4899"/>
                <participants group_id="P3" count="1860"/>
                <participants group_id="P4" count="2084"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Data ended end of 2010</title>
              <participants_list>
                <participants group_id="P1" count="1764"/>
                <participants group_id="P2" count="2880"/>
                <participants group_id="P3" count="1140"/>
                <participants group_id="P4" count="1194"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medicaid eligibility discontinued</title>
              <participants_list>
                <participants group_id="P1" count="1478"/>
                <participants group_id="P2" count="2019"/>
                <participants group_id="P3" count="720"/>
                <participants group_id="P4" count="890"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Antipsychotic</title>
          <description>Individuals initiating treatment with an antipsychotic medication
Antipsychotic: New initiation of any antipsychotic medication</description>
        </group>
        <group group_id="B2">
          <title>Antidepressant</title>
          <description>Individuals initiating treatment with an antidepressant medication
Antidepressant: New initiation of any antidepressant medications</description>
        </group>
        <group group_id="B3">
          <title>Benzodiazepine</title>
          <description>Individuals initiating treatment with a benzodiazepine
Benzodiazepine: New initiation of any benzodiazepine</description>
        </group>
        <group group_id="B4">
          <title>Mood Stabilizer</title>
          <description>Individuals initiating treatment with a mood stabilizer
Mood stabilizer: New initiation of lithium or any mood stabilizing anti-epileptic drug</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26014"/>
            <count group_id="B2" value="31117"/>
            <count group_id="B3" value="11941"/>
            <count group_id="B4" value="12849"/>
            <count group_id="B5" value="81921"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.5" spread="12.5"/>
                    <measurement group_id="B2" value="40.5" spread="12.4"/>
                    <measurement group_id="B3" value="40.5" spread="12.5"/>
                    <measurement group_id="B4" value="40.3" spread="12.5"/>
                    <measurement group_id="B5" value="40.5" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11914"/>
                    <measurement group_id="B2" value="14283"/>
                    <measurement group_id="B3" value="5553"/>
                    <measurement group_id="B4" value="5975"/>
                    <measurement group_id="B5" value="37725"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14100"/>
                    <measurement group_id="B2" value="16834"/>
                    <measurement group_id="B3" value="6388"/>
                    <measurement group_id="B4" value="6874"/>
                    <measurement group_id="B5" value="44196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9645"/>
                    <measurement group_id="B2" value="10998"/>
                    <measurement group_id="B3" value="5186"/>
                    <measurement group_id="B4" value="4261"/>
                    <measurement group_id="B5" value="30090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10371"/>
                    <measurement group_id="B2" value="12459"/>
                    <measurement group_id="B3" value="3731"/>
                    <measurement group_id="B4" value="5465"/>
                    <measurement group_id="B5" value="32026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2517"/>
                    <measurement group_id="B2" value="3196"/>
                    <measurement group_id="B3" value="1159"/>
                    <measurement group_id="B4" value="1263"/>
                    <measurement group_id="B5" value="8135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="645"/>
                    <measurement group_id="B2" value="461"/>
                    <measurement group_id="B3" value="252"/>
                    <measurement group_id="B4" value="237"/>
                    <measurement group_id="B5" value="1595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hawaiian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="782"/>
                    <measurement group_id="B2" value="744"/>
                    <measurement group_id="B3" value="339"/>
                    <measurement group_id="B4" value="287"/>
                    <measurement group_id="B5" value="2152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="240"/>
                    <measurement group_id="B2" value="305"/>
                    <measurement group_id="B3" value="104"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="736"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2763"/>
                    <measurement group_id="B2" value="2787"/>
                    <measurement group_id="B3" value="1152"/>
                    <measurement group_id="B4" value="1223"/>
                    <measurement group_id="B5" value="7925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Psychiatric Hospitalization</title>
        <description>Number of participants hospitalized for a mental health reason</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antipsychotic</title>
            <description>Individuals initiating treatment with another second-generation antipsychotic medication (other than clozapine</description>
          </group>
          <group group_id="O2">
            <title>Antidepressant</title>
            <description>Individuals initiating treatment with an antidepressant medication</description>
          </group>
          <group group_id="O3">
            <title>Benzodiazepine</title>
            <description>Individuals initiating treatment with a benzodiazepine</description>
          </group>
          <group group_id="O4">
            <title>Mood Stabilizer</title>
            <description>Individuals initiating treatment with a mood stabilizer</description>
          </group>
        </group_list>
        <measure>
          <title>Psychiatric Hospitalization</title>
          <description>Number of participants hospitalized for a mental health reason</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26014"/>
                <count group_id="O2" value="31117"/>
                <count group_id="O3" value="11941"/>
                <count group_id="O4" value="12849"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4965"/>
                    <measurement group_id="O2" value="5247"/>
                    <measurement group_id="O3" value="2385"/>
                    <measurement group_id="O4" value="3093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Emergency Department Visit for Mental Health Reason</title>
        <description>Number of Participants with an Emergency Department visit for mental health reason</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antipsychotic</title>
            <description>Individuals initiating treatment with another second-generation antipsychotic medication (other than clozapine)</description>
          </group>
          <group group_id="O2">
            <title>Antidepressant</title>
            <description>Individuals initiating treatment with an antidepressant medication</description>
          </group>
          <group group_id="O3">
            <title>Benzodiazepine</title>
            <description>Individuals initiating treatment with a benzodiazepine</description>
          </group>
          <group group_id="O4">
            <title>Mood Stabilizer</title>
            <description>Individuals initiating treatment with a mood stabilizer</description>
          </group>
        </group_list>
        <measure>
          <title>Emergency Department Visit for Mental Health Reason</title>
          <description>Number of Participants with an Emergency Department visit for mental health reason</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26014"/>
                <count group_id="O2" value="31117"/>
                <count group_id="O3" value="11941"/>
                <count group_id="O4" value="12849"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5505"/>
                    <measurement group_id="O2" value="6508"/>
                    <measurement group_id="O3" value="2930"/>
                    <measurement group_id="O4" value="3429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death</title>
        <description>Participants who died</description>
        <time_frame>One year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Antipsychotic</title>
            <description>Individuals initiating treatment with another second-generation antipsychotic medication (other than clozapine)</description>
          </group>
          <group group_id="O2">
            <title>Antidepressant</title>
            <description>Individuals initiating treatment with an antidepressant medication</description>
          </group>
          <group group_id="O3">
            <title>Benzodiazepine</title>
            <description>Individuals initiating treatment with a benzodiazepine</description>
          </group>
          <group group_id="O4">
            <title>Mood Stabilizer</title>
            <description>Individuals initiating treatment with a mood stabilizer</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>Participants who died</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26014"/>
                <count group_id="O2" value="31117"/>
                <count group_id="O3" value="11941"/>
                <count group_id="O4" value="12849"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="327"/>
                    <measurement group_id="O3" value="204"/>
                    <measurement group_id="O4" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>365 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Antipsychotic</title>
          <description>Individuals initiating treatment with another second-generation antipsychotic medication (other than clozapine)</description>
        </group>
        <group group_id="E2">
          <title>Antidepressant</title>
          <description>Individuals initiating treatment with an antidepressant medication</description>
        </group>
        <group group_id="E3">
          <title>Benzodiazepine</title>
          <description>Individuals initiating treatment with a benzodiazepine</description>
        </group>
        <group group_id="E4">
          <title>Mood Stabilizer</title>
          <description>Individuals initiating treatment with a mood stabilizer</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="259" subjects_at_risk="26014"/>
                <counts group_id="E2" subjects_affected="327" subjects_at_risk="31117"/>
                <counts group_id="E3" subjects_affected="204" subjects_at_risk="11941"/>
                <counts group_id="E4" subjects_affected="161" subjects_at_risk="12849"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="26014"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="31117"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="11941"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="12849"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Admission for Cardiovascular Disease</sub_title>
                <description>Defined by first listed diagnosis of acute myocardial infarction (AMI) (ICD-9-CM: 410) or stroke (430-438, except 435) on inpatient claims.</description>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="26014"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="31117"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="11941"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="12849"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="967" subjects_at_risk="21738"/>
                <counts group_id="E2" subjects_affected="1004" subjects_at_risk="26062"/>
                <counts group_id="E3" subjects_affected="424" subjects_at_risk="9764"/>
                <counts group_id="E4" subjects_affected="423" subjects_at_risk="10564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Incident cases of diabetes mellitus</sub_title>
                <counts group_id="E1" events="967" subjects_affected="967" subjects_at_risk="21738"/>
                <counts group_id="E2" events="1004" subjects_affected="1004" subjects_at_risk="26062"/>
                <counts group_id="E3" events="424" subjects_affected="424" subjects_at_risk="9764"/>
                <counts group_id="E4" events="423" subjects_affected="423" subjects_at_risk="10564"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Scott Stroup</name_or_title>
      <organization>Columbia University</organization>
      <phone>646-774-8435</phone>
      <email>Scott.Stroup@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

